VITRUVIAN BIO, LLC

VITRUVIAN BIO, LLC specializes in the design and development of point-of-care diagnostic platforms for infectious disease detection, with a focused expertise in electrochemical biosensors and nucleic acid-based testing for HIV-1. The company leverages integrated microfluidics, label-free signal transduction, and self-monitoring device architectures to enable rapid, low-cost viral load and drug adherence monitoring in resource-limited settings. Their technical capabilities span electrochemical sensing, assay development for nucleic acid amplification, and portable instrumentation design, with a strong emphasis on translating laboratory innovations into field-deployable diagnostics. Key differentiators include the integration of user-centric design with clinical workflow compatibility and the application of robust, low-power signal processing for decentralized testing environments. VITRUVIAN BIO, LLC has established a consistent relationship with the Department of Health and Human Services, primarily through SBIR-phase funding mechanisms supporting high-impact public health diagnostics. Their work with HHS centers on advancing early detection tools for HIV, aligning with national initiatives to improve viral suppression and treatment adherence through innovative point-of-care technologies. The contractor’s core industry focus lies in biotechnology research and life sciences R&D, specifically within NAICS 541714 and 541715, where they bridge molecular diagnostics, biomedical engineering, and clinical diagnostics. Their market positioning is as a nimble innovator in next-generation infectious disease monitoring, targeting gaps in global health surveillance and community-based testing infrastructure. As a Women-Owned Small Business and Woman-Owned Business certified entity headquartered in Baltimore, MD, VITRUVIAN BIO, LLC operates as a small, agile firm with deep technical specialization in diagnostic device development. Their certifications enhance their eligibility for targeted federal innovation programs and reflect a commitment to diversity in biomedical R&D leadership.